Malaysia

Current Distributors Profile

Our network has distributors that have product categories that include including Consumable products such as lab chemicals and reagents, plasticware and glassware; Lab Equipment ranging from hand held micropipettes to Liquid Handling Robots, cell culture incubators to industrial use fermenters, dry bath incubators to PCR Thermocyclers and many more. They also sell Diagnostic products such as blood collections Bacterial ID and AST, and molecular diagnostic and IVF kits.  They also offer custom service for NGS, oligonucleotides, gene construction, custom peptides and antibodies.

These distributors maintain a staff of highly technical salespeople, and application specialists, customer and technical service members and logistical and warehousing personnel.

These distributors also market through domestic exhibitions, websites, catalogue and brochures, in house workshops sales, and product specific promotions and ad campaigns.

b2b connect has a relationship with distributors in Malaysia that we can contact to see which one may be a good fit with your product portfolio.

Market

Our partners in Malaysia have products spanning the Life Science industry ranging from cages for research animals to molecular biology reagents to Bioinformatics.  They also can stock and

Since 2005, when then-Prime Minister Abdullah Badawi launched the 15-year National Biotechnology Policy, with a goal of generating 5% of GDP by 2020, progress has been steady and said it was committed to advancing more collaborations with industry partners.

Malaysia is seventh in jobs with 31,000, and companies. Malaysian Bioeconomy Development’s website listed 250 “BioNexus” designated businesses as of October 10—though a September 25 news report stated the figure was 285, of which 60% were in agriculture, 24% biomedical, and the rest bioindustrial. Malaysia remains eighth in both R&D ($9.728 billion according to UNESCO) and patents (ninth with 357 listing at least one Malaysian inventor, according to WIPO). Malaysia has not seen a biotech IPO since Bioalpha Holdings raised $5 million in 2015.